Aytu Biopharma Inc to Discuss the Rumpus Transaction and the AR101 Scientific Background- Conference Call Transcript
Good afternoon, and thank you for joining us for the Aytu BioPharma webcast and conference call discussing the company's acquisition of the assets of Rumpus Therapeutics. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbrow. And Mr. Disbrow is joined by Dr. Hal Dietz, Professor of Genetic Medicine at Johns Hopkins University School of Medicine and Investigator at Howard Hughes Medical Institute.
Aytu BioPharma issued a press release this morning with details of the company's acquisition of the Rumpus Therapeutics' Rare Disease assets. A copy of the press release is available on the news page of the company's website at aytubio.com.
I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available on the company's website following this call. In addition, a webcast will be accessible live and archived on Aytu's website within the Investors section under Events & Presentations at aytubio.com.
Finally, I'd like to call your attention to the customary safe harbor disclosure regarding forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |